

TITLE

Inter-individual differences in the blood pressure lowering effects of dietary nitrate: A randomised double-blind placebo-controlled replicate crossover trial

AUTHORS

Eleanor Hayes^{1,2}, Shatha Alhulaefi^{1,3}, Mario Siervo^{4,5}, Eleanor Whyte⁶, Rachel Kimble⁷, Jamie Matu⁸, Alex Griffiths⁸, Marc Sim^{9,10}, Mia Burleigh⁷, Chris Easton⁷, Lorenzo Lolli¹¹, Greg Atkinson¹², John C Mathers¹, Oliver M Shannon¹

AFFILIATIONS

¹ Human Nutrition & Exercise Research Centre, Centre for Healthier Lives, Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

² Northumbria University, Newcastle upon Tyne, UK.

³ Department of Nutrition, Taif University, Taif 21944, Saudi Arabia.

⁴ School of Population Health, Curtin University, Perth, WA, Australia.

⁵ Curtin Dementia Centre of Excellence, Enable Institute, Curtin University, Perth, Australia.

⁶ Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

⁷ Sport and Physical Activity Research Institute, University of the West of Scotland, Blantyre, Scotland, UK.

⁸ School of Health, Leeds Beckett University, Leeds, UK.

⁹ Nutrition and Health Innovation Research Institute, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.

¹⁰ Medical School, The University of Western Australia, Perth, Western Australia, Australia.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹¹ Department of Sport and Exercise Sciences, Institute of Sport, Manchester Metropolitan University, Manchester, UK.

¹² School of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK.

CORRESPONDENCE:

Name: Dr. Oliver M Shannon

Email: Oliver.Shannon@Newcastle.ac.uk

Telephone: 01912081140

1 ABSTRACT

2 **Purpose:** Dietary nitrate supplementation increases nitric oxide (NO) bioavailability and
3 reduces blood pressure (BP). Inter-individual differences in these responses are suspected
4 but have not been investigated using robust designs, e.g., replicate crossover, and appropriate
5 statistical models. We examined the within-individual consistency of the effects of dietary
6 nitrate supplementation on NO biomarkers and BP, and quantified inter-individual response
7 differences.

8 **Methods:** Fifteen healthy males visited the laboratory four times. On two visits, participants
9 consumed 140ml nitrate-rich beetroot juice (~14.0mmol nitrate) and, on the other two visits,
10 they consumed 140ml nitrate-depleted beetroot juice (~0.03mmol nitrate). Plasma nitrate and
11 nitrite concentrations were measured 2.5 hours post-supplementation. BP was measured pre-
12 and 2.5 hours post-supplementation. Between-replicate correlations were quantified for the
13 placebo-adjusted post-supplementation plasma nitrate and nitrite concentrations and pre-to-
14 post changes in BP. Within-participant linear mixed models (LLM) and a meta-analytic
15 approach estimated participant-by-condition treatment response variability.

16 **Results:** Nitrate-rich beetroot juice supplementation elevated plasma nitrate and nitrite
17 concentrations and reduced systolic (mean:-7mmHg, 95%CI: -3 to -11mmHg) and diastolic
18 (mean:-6mmHg, 95%CI: -2 to -9mmHg) BP *versus* placebo. The LLM participant-by-
19 condition interaction response variability was ± 7 mmHg (95%CI: 3 to 9mmHg) for systolic
20 BP and consistent with the treatment effect heterogeneity $\tau = \pm 7$ mmHg (95%CI: 5 to
21 12mmHg) derived from the meta-analytic approach. The between-replicate correlations were
22 moderate-to-large for plasma nitrate, nitrite and systolic BP ($r=0.55$ to 0.91).

23 **Conclusions:** The effects of dietary nitrate supplementation on NO biomarkers and systolic
24 BP varied significantly from participant to participant. The causes of this inter-individual

25 variation deserve further investigation. Trial registration:

26 <https://clinicaltrials.gov/study/NCT05514821>.

27

28 **KEY WORDS:** Dietary nitrate; beetroot juice; blood pressure; hypertension; individual

29 differences; inter-individual variation

30 INTRODUCTION

31 High blood pressure (BP) is a leading cause of morbidity and mortality worldwide [1], and
32 the identification of effective strategies to lower BP remains a major research and public
33 health priority [2, 3]. Consumption of a healthy diet can lower BP and is recommended as a
34 first line treatment for low grade hypertension and as an adjunct to BP-lowering
35 pharmacotherapy for more severe hypertension [4]. Various dietary approaches have been
36 demonstrated to help lower BP, including consumption of dietary compounds/foods with
37 potential anti-hypertensive properties such as dietary inorganic nitrate [5–7].

38 For most people, the major dietary sources of inorganic nitrate are vegetables such as
39 lettuce, spinach and beetroot [8, 9], and this nitrate serves as a precursor for nitric oxide (NO)
40 – a gaseous signalling molecule with vasodilatory properties [10, 11]. Consumption of
41 nitrate-rich vegetables or vegetable juices (e.g., [6, 12–14]), and nitrate salts (e.g., [5, 15,
42 16]), has been shown to elevate NO biomarkers (e.g., plasma nitrate and nitrite
43 concentrations) and lower BP both acutely (within hours of supplementation) and chronically
44 (over several weeks/months) [7]. However, individual differences in the response to nitrate
45 have been suggested, with some researchers hypothesising the existence of individuals
46 deemed ‘*responders*’ and ‘*non-responders*’ to nitrate supplementation [17–21]. If correct,
47 this notion could have important implications for the development of personalised
48 recommendations around nitrate intake. For example, if it is possible to identify the
49 individuals most likely to benefit from nitrate supplementation, then these individuals could
50 be targeted for nitrate-based interventions in future trials and public health initiatives.

51 Identification of meaningful inter-individual differences in response to nutritional
52 interventions can be challenging. Notably, with conventional parallel-arm or crossover trials,
53 it is not possible to determine whether any apparent difference between participants in the
54 changes from pre- to post-intervention are due to genuine treatment response heterogeneity or

55 are a consequence of random within-subject variability and/or measurement error [22].
56 Without repeated administration of trials, a typical crossover design does not allow formal
57 estimation of variance attributable to the participant-by-treatment interaction [23, 24]. Only
58 with knowledge about this interaction can treatment response heterogeneity be quantified
59 properly. As a form of *n-of-1* trial, a replicate crossover trial constitutes a pragmatic research
60 design for quantifying treatment response heterogeneity [22, 23, 25]. This research design
61 involves repeated administration of the intervention and control/placebo arms of a trial
62 protocol in randomised order on at least two occasions. This allows quantification of
63 treatment response heterogeneity using, for example, a within-participant covariate-adjusted
64 linear mixed model for estimation of any participant-by-treatment interaction effects [22, 23,
65 25].

66 We aimed to quantify the magnitude of inter-individual variability in the effects of
67 dietary nitrate supplementation on the outcomes of NO biomarkers and BP using a replicate
68 crossover design. We also aimed to examine the consistency of these responses on repeated
69 occasions. We hypothesized that there is ‘*true*’ inter-individual variability (i.e., exceeding
70 random within-subject variability) in the effects of dietary nitrate supplementation on NO
71 biomarkers and BP, and that these responses would be consistent on two occasions.

72

73 **METHODS**

74 The protocol for this study was registered prospectively on ClinicalTrials.gov
75 (NCT05514821). The study was approved by the Faculty of Medical Sciences Research
76 Ethics Committee at Newcastle University (2345/23609).

77

78

79

80 **Participants**

81 Healthy male participants were recruited from the general population via posters, university
82 email lists, and social media to take part in this study (see Supplementary Figure 1 for
83 CONSORT flow chart). Participants were required to be non-smokers who were not
84 currently taking any medication or using any dietary supplements, had no history of
85 cardiovascular, metabolic, or gastrointestinal diseases, and were not currently using
86 antibacterial mouthwash.

87

88 **Design**

89 Participants attended the laboratory on 5 separate occasions (data collection period: October
90 2022 to September 2023). On the first visit, participants provided written informed consent
91 and underwent screening to determine eligibility to participate. A pre-screening
92 questionnaire was completed, and body mass and stature were measured. Subsequently,
93 participants completed four experimental visits (two nitrate and two placebo) in a randomised
94 order. A randomised sequence schedule (see Supplementary Text 1) was created using
95 <http://www.randomization.com>) for our replicate crossover experimental research design
96 [25]. Experimental visits were separated by ~7 days (minimum 3 days, maximum 14 days).
97 Participants were asked to record their diet in the 24 hours prior to the first visit and to
98 replicate this as closely as possible prior to each subsequent visit. Participants were asked to
99 abstain from intensive exercise and alcohol in the 24 hours prior to each visit and were
100 instructed to avoid consumption of any food or drink except for plain water on the morning
101 on the experimental visits.

102

103

104

105 **Experimental visits**

106 Participants arrived at the laboratory between 8 and 9 am and rested, seated in quiet room for
107 10 minutes. Subsequently, systolic and diastolic BP of the brachial artery was measured
108 using an automated sphygmomanometer following best-practice guidelines [26]. Four
109 measurements were taken, with the mean of the final three measurements used for subsequent
110 analyses. Participants then received a standardised breakfast including 140 ml concentrated
111 nitrate-rich (~14.0 mmol nitrate) or nitrate-depleted (~0.03 mmol nitrate) beetroot juice and a
112 bowl of porridge (60g oats, 200 ml whole milk). We used commercially available beetroot
113 juice supplements (Beet It Sport, James White Drinks Ltd., Ipswich, UK). All supplements
114 were from the same batch, with each batch undergoing homogenisation during manufacturing
115 to maximise consistency in the nitrate concentrations. We analysed a single bottle each of the
116 ‘active’ and placebo supplement using the same chemiluminescence approach outlined below
117 to provide indicative nitrate concentrations. Supplements were administered double blind.
118 Participants then rested, seated in a quiet room for 2.5 hours during which time they were
119 permitted to carry out non-stimulating activities (e.g., reading). Blood pressure
120 measurements were then repeated, and a blood sample was collected via venepuncture of an
121 antecubital vein into two, 4 ml lithium heparin containing tubes (Vacutainer, Becton
122 Dickinson, Plymouth, UK). Samples were immediately centrifuged at 3000 rpm and 4°C for
123 10 minutes, plasma was extracted and frozen at -80°C. Participants were then free to leave
124 the laboratory.

125

126 **Biochemical analyses**

127 Measurements of plasma nitrate and nitrite concentrations were conducted using ozone-based
128 chemiluminescence [27]. For the measurement of plasma nitrate concentration, vanadium
129 reagent (24 mg of vanadium tri-chloride and 3 ml of 1M hydrochloric acid) and 100 µL of

130 anti-foaming agent were placed into a glass purge vessel infused with nitrogen and heated to
131 95°C. This purge vessel was connected to a NO analyser (Sievers NOA 280i, Analytix, UK).
132 A standard curve was produced by injecting 25 µL of nitrate solutions (100 µM, 50 µM, 25
133 µM, 12.5 µM, and 6.25 µM) and a control sample containing deionised water. The area
134 under the curve (AUC) for the control sample was subtracted from those for the nitrate
135 solutions to account for nitrate in the water used for dilutions. Plasma samples were thawed
136 in a water bath at 37°C for 3 min and de-proteinised using zinc sulphate/sodium hydroxide
137 solution (200 µL of plasma, 400 µL of zinc sulphate in deionised water at 10% w/v and 400
138 µL of 0.5M sodium hydroxide). The samples were then vortexed for 30 s before being spun at
139 4000 rpm for 5 min. Subsequently, 15-25 µL of the sample was injected into the purge vessel
140 in duplicate. The concentration of NO produced was then measured by the NO analyser. The
141 AUC was calculated using Origin software (version 7) and normalised using the Y value
142 from the calibration curve.

143

144 For the measurement of plasma nitrite concentrations, 2.5 ml glacial acetic acid, 0.5 ml of 18
145 Ω deionised water, 25 mg sodium iodide, and 100 µL of an anti-foaming agent were placed
146 into the glass purge vessel and heated to 50°C. A standard curve was produced by injecting
147 100 µL of nitrite solutions (1000 nM, 500 nM, 250 nM, 125 nM, and 62.5 nM) and a control
148 sample of deionised water. The AUC for the latter was subtracted from those for the nitrite
149 solutions to account for nitrite in the water used for dilutions. Following this, plasma samples
150 were thawed in a water bath and 100 µL of the sample was injected into the purge vessel in
151 duplicate. The nitrite concentration was determined via the AUC, as described for nitrate
152 analysis.

153

154

155 **Statistical analysis**

156 We adopted a pragmatic approach to sample size considerations [28, 29]. Given the onerous
157 nature of the four-condition replicate design and procedures, we recruited 15 participants,
158 which is a sample size similar to previous replicate crossover trials in nutrition research [30,
159 31]. As detailed below, the between-replicate correlation coefficient is an indicator of
160 individual stability of response. Using GPower (version 3.1), we estimated the minimum
161 statistically significant between-replicate correlation coefficient to be 0.44 for a sample size
162 of 15. The 90% confidence interval (CI) for this correlation coefficient is estimated to be 0.01
163 to 0.74. A one-tailed directional hypothesis (90% CI) is relevant here because the null
164 hypothesis (H_0) is that $r = 0$ OR <0 , i.e., if the correlation is either zero or negative, this
165 would lead to the same conclusion (non-rejection of H_0) of no consistent responses being
166 present [32].

167

168 The analysis protocol (which included data for all 15 participants) followed a four-step
169 approach consistent with previous research [30, 31, 33] and more recent advances [34]
170 relevant to the elaboration of continuous data from a replicate crossover trial designed
171 experiment. Primary outcome measures were systolic and diastolic BP. Secondary outcome
172 measures were plasma nitrate and plasma nitrite. First, we estimated Pearson's product
173 moment correlation coefficients between the first and second response replicates for each
174 outcome to assess the within-person stability of the replicated placebo-adjusted
175 supplementation effect [22] - a high correlation between the two repeated responses
176 indicating a relatively stable individual response. For this correlation analysis of consistency
177 of response, the first supplementation condition of each participant was paired to their
178 respective first placebo condition in their individual sequence and the placebo-adjusted
179 supplementation effect was computed for response 1 (supplementation 1 *minus* placebo 1 for

180 BP changes). This process was replicated for the second condition pairs to calculate response
181 2 (supplementation 2 *minus* placebo 2).

182

183 Second, an overall “naive” estimate of the true individual difference standard deviation (SD)
184 for the supplementation response was derived using the following approach [23]:

185
$$SD_{IR} = \sqrt{SD_S^2 - SD_P^2}$$

186 The SD_{IR} value in the equation is the SD of the individual differences in the supplementation
187 response (SD_S) adjusted for the standard deviation in the placebo conditions (SD_P),
188 respectively [23]. A positive SD_{IR} indicates that the variability in supplementation response is
189 greater than any random within-subject variability. This calculation is considered a naive
190 estimation of the SD_{IR} because it is not derived from a statistical model on the raw data and
191 was originally formulated with parallel arm studies in mind. Specifically, our design is of a
192 within-subjects nature rather than a parallel-arm study.

193

194 Third, and in view of the issues above with the naive estimate of SD_{IR} , we used the PROC
195 MIXED procedure in SAS OnDemand for Academics (SAS Institute) to derive the SD_{IR} , in
196 line with previous studies [23]. Distinct within-participant covariate-adjusted linear mixed
197 models were used to quantify inter-individual differences in NO biomarkers and blood
198 pressure responses specified as participant-by-condition interaction terms, with the variance-
199 covariance matrix structure set to *variance components* [22, 25, 35]. Each model included the
200 outcome measure specified as response variable, condition, period (condition sequence) and
201 the period-by-condition interaction included as fixed effects, with participant and the
202 participant-by-condition interaction modelled as random effects (Supplemental File 1). The
203 variance for the participant by condition interaction indicates the degree of response

204 heterogeneity and the P-value for this interaction represents whether the variance can be
205 considered statistically significant from zero (no response heterogeneity). The adequacy of
206 the modelled covariance parameter estimates was assessed via formal residual diagnostics
207 procedures [36, 37]. Effects were reported as estimated marginal means alongside relevant
208 measures of dispersion (SD) and uncertainty (95% CI). Using data from prognostic studies in
209 cardiovascular medicine as a guide, we defined a $\Delta=2$ mmHg reduction in systolic and
210 diastolic BP as the minimal clinically important difference (MCID) when interpreting the
211 meaningfulness of interindividual response differences [38, 39].

212

213 Fourth, according to Senn's meta-analytical approach, a sample estimate of within-subjects
214 variance was calculated and converted to a standard error using appropriate degrees of
215 freedom to derive replicate-averaged treatment effects for each participant [34]. Using the
216 *metagen()* function available in the *meta* package [40], we conducted a random-effects meta-
217 analysis with Hartung-Knapp adjustment [41] to summarise individual-participant replicate-
218 averaged treatment effects and respective sampling errors [34]. The restricted maximum-
219 likelihood estimation method determined the tau-statistic (τ) value describing the between-
220 participant replicate-averaged treatment effect response variability across the distribution of
221 true treatment effects [42, 43]. As Senn [34] explained, there are typically few degrees of
222 freedom per individual in an n-of-1 trial, so it is better to use a pooled variance in the meta-
223 analysis, resulting in the same variance estimate being applied to each person in the case of a
224 replicate crossover where the number of replicates is the same for each individual. The
225 generalised Q-statistic method estimated the uncertainty surrounding the point τ -statistic
226 value reported as 95% CI [44]. Weighted raw replicate-averaged treatment effect differences
227 were presented as descriptive statistics together with the respective 95% prediction interval
228 (95% PI) illustrating the range for the distribution of true mean differences expected for 95%

229 of similar future studies [45, 46]. Meta-analyses were conducted in R (version 3.6.3, R
230 Foundation for Statistical Computing); see Supplementary file 1 for the associated R
231 Markdown file.

232
233 Additional exploratory analyses involved post-hoc correlations (Pearson's correlation)
234 estimated to examine relationships between plasma nitrite and nitrate with BP variables.
235 Relationships were further examined using within-participant covariate-adjusted linear mixed
236 effects models including the BP change score as dependent variable, plasma nitrite,
237 condition, period, and the period-by-condition interaction as fixed effects plus a study
238 participant random effect using the *xtmixed* command (StataMP v14.1; StataCorp LP,
239 College Station, TX). Estimated marginal means described the expected BP changes at pre-
240 specified plasma nitrite concentrations whose uncertainty was presented as 95%CI and
241 derived using the *margins* commands [47].

242

243 **RESULTS**

244 Fifteen healthy male participants with mean (SD) age of 27 (5) years and BMI of 24.0 (4.1)
245 kg/m² took part in this study.

246

247 **Plasma nitrate concentration**

248 There was a strong positive correlation ($r=0.91$, 90%CI: 0.78 to 0.96) between the two sets of
249 placebo-adjusted responses to nitrate supplementation for plasma nitrate concentration
250 (Figure 1A). The within-trial SD for plasma nitrate concentration was substantially greater
251 for the nitrate supplementation *versus* placebo conditions (Table 1). The model-based
252 treatment-by-condition interaction response variability was ± 45 uM (95%CI, 22 to 60 uM).
253 Linear mixed models revealed a main effect of condition ($p<0.001$), with a larger mean

254 plasma nitrate concentration of 225 μM (95% CI: 199 to 250 μM) in the nitrate
255 supplementation *versus* placebo condition. When averaged over the two replicates, the
256 placebo-controlled post-supplementation mean plasma nitrate concentration ranged from 163
257 to 300 μM between the participants (Figure 2A). The meta-analytic approach-estimated
258 between-participant replicate-averaged treatment effect nitrate response heterogeneity (τ) was
259 ± 43 μM (95% CI: 30 to 69 μM).


260

261 **Plasma nitrite concentration**

262 There was a moderate positive correlation ($r=0.55$, 90% CI: 0.14 to 0.80) between the two sets
263 of placebo-adjusted responses to dietary nitrate supplementation for plasma nitrite
264 concentration (Figure 1B). The within trial SD for plasma nitrite concentration was
265 substantially greater for the nitrate supplementation versus placebo conditions (Table 1), with
266 the model-based treatment-by-condition interaction response variability of ± 324 (95% CI: 125
267 to 441 nM). Linear mixed models revealed a significant main effect of condition ($p<0.001$),
268 with the mean plasma nitrite concentration 461 nM higher (95% CI, 269 to 653 nM) in the
269 nitrate supplementation versus placebo condition. When averaged over the two replicates, the
270 placebo-controlled post-supplementation mean plasma nitrite concentration ranged from 126
271 to 961 nM between the participants (Figure 2B). The meta-analytic approach-estimated
272 between-participant replicate-averaged treatment effect nitrite response heterogeneity (τ) was
273 ± 224 nM (95% CI: 132 to 394 nM).

274

275




276

277

278 **Figure 1.** Individual panels present the relationship between the placebo-adjusted plasma
279 nitrate concentrations (uM, panel A), plasma nitrite concentrations (nM, panel B), systolic BP
280 (mmHg, panel C), and diastolic BP (mmHg, panel D) on the two occasions. “Response 1”
281 reflects data for the first pair of conditions (nitrate 1 minus placebo 1) and “response 2” for the
282 second pair of conditions (nitrate 2 minus placebo 2). The dashed vertical and horizontal lines
283 reflect the mean responses.

284



285

286 **Figure 2.** Forest plots for the plasma nitrate (A) and nitrite (B) summary effects and between-
 287 participant (τ) replicated-averaged treatment effect heterogeneity. τ , denotes tau-statistic; CI,
 288 denotes confidence interval.

289

290 **Systolic BP**

291 There was a strong positive correlation ($r=0.80$, 90% CI: 0.55 to 0.92) between the two sets of
 292 placebo-adjusted responses to dietary nitrate supplementation for systolic BP (Figure 1C).

293 The within trial SD for systolic BP was substantially greater for the nitrate supplementation
 294 *versus* placebo conditions, and the model-based treatment-by-condition interaction response
 295 variability was ± 7 mmHg (95% CI: 3 to 9 mmHg) (Table 1). Linear mixed models revealed a
 296 main effect of condition ($p=0.001$), with a mean reduction in systolic BP that was 7 mmHg
 297 (95% CI: 3 to 11 mmHg) greater in the nitrate supplementation *versus* the placebo condition.

298 When averaged over the two replicates, the placebo-controlled nitrate supplementation
 299 response ranged from a 9 mmHg increase to a 24-mmHg reduction between the participants
 300 (Figure 3A). The meta-analytic approach revealed the upper confidence limit for the

301 between-participant replicate-averaged treatment effect heterogeneity of $\tau = \pm 7$ mmHg

302 (95% CI: 5 to 12 mmHg) surpassed the clinically relevant target reduction of 2 mmHg for 8

303 participants (Figure 3A).


304

305

306

307 **Diastolic BP**

308 Correlations between the two sets of placebo-adjusted responses to dietary nitrate
 309 supplementation for diastolic BP were small and non-significant ($r=0.06$, 90% CI: -0.39 to
 310 0.49, Figure 1D). The within trial SD for diastolic BP was similar for the dietary nitrate
 311 versus placebo conditions, with the model-based treatment-by-condition interaction response
 312 variability of ± 3 mmHg (95%CI: -4 to 6 mmHg; Table 1). Linear mixed models revealed a
 313 significant main effect of condition ($p=0.003$), with a mean reduction in diastolic BP of 6
 314 mmHg lower (95%CI: 2 to 9 mmHg lower) in the nitrate supplementation *versus* placebo
 315 condition. When averaged over the two replicates, the placebo-controlled nitrate
 316 supplementation response ranged from a 1 mmHg increase to a 21-mmHg reduction between
 317 the participants (Figure 3B). The meta-analytic approach revealed the upper confidence limit
 318 for the between-participant replicate-averaged treatment effect heterogeneity of $\tau = \pm 2$
 319 mmHg (95%CI: 0 to 8 mmHg) surpassed the clinically relevant target reduction of 2 mmHg
 320 for 2 participants (Figure 3B).
 321



322 **Figure 3.** Forest plots for systolic BP (A) and diastolic BP (B) summary effects and between-
 323 participant (t) replicated-averaged treatment effect heterogeneity. The red dashed line
 324 indicates the target difference reduction of 2 mmHg. τ , denotes tau-statistic; CI, denotes
 325 confidence interval.
 326

327 **Table 1.** Estimated marginal means and SEs for primary outcome measures in the supplementation and placebo conditions with the true
 328 individual differences SD.

Outcome	Mean (SE)		Main effect of condition Mean difference (95% CI)	Estimate 1 ¹ Individual differences SD	Estimate 2 ² Individual differences SD (95% CI)	<i>P</i> value (<i>int</i>)
	Supplementation	Placebo				
Plasma nitrate concentration (uM)	239 (12)	15 (2)	225 (199 to 250)	44	45 (22 to 60)	0.0104
Plasma nitrite concentration (nM)	570 (85)	109 (12)	461 (269 to 653)	308	324 (125 to 441)	0.0214
Systolic blood pressure (mmHg)	-7 (2)	1 (1)	-7 (-11 to -3)	6	7 (3 to 9)	0.0196
Diastolic blood pressure (mmHg)	5 (3)	1 (1)	-6 (-9 to -2)	2	3 (-4 to 6)	0.5107

329 Data for the analysis involved 60 experimental conditions in $n = 15$ males. Systolic and diastolic blood pressure values were obtained immediately
 330 prior to, and 2.5 hours following, nitrate or placebo supplementation and data reflect the change in pre-to-post intervention values. Blood samples
 331 were obtained 2.5 hours post supplementation only, therefore data for plasma nitrate and nitrite concentrations reflect post-supplementation values
 332 only.

333 ¹Estimate 1: A naive estimate of the individual differences SD using the simple equation of $SD_{IR} = \sqrt{SD_S^2 - SD_P^2}$ where SD_{IR} is the SD of the true
 334 individual response, and SD_S and SD_P are the SDs of the primary outcome measures in the supplementation and placebo conditions, respectively
 335 [23]

336 ²Estimate 2: Individual differences SD estimated using a random effects within-subjects statistical model [25]. The SD was calculated from the
 337 participant-by-condition interaction term modelled as a random effect and the *P* value is for this interaction term.

338 SE, standard error; SD, standard deviation; CI, confidence interval; *int*, participant-by-condition interaction.

339

340 **Correlations amongst outcome variables**

341 There was a small, non-significant positive correlation ($r=0.37$, 90%CI: -0.09 to 0.70,
342 $p=0.09$) between the placebo-adjusted plasma nitrate and nitrite concentrations following
343 dietary nitrate supplementation. In addition, there were small, non-significant negative
344 correlations between the placebo-adjusted plasma nitrate concentrations and the change in
345 both systolic ($r=-0.20$, 90%CI: -0.59 to 2.63, $p=0.23$) and diastolic ($r=-0.26$, 90%CI: -0.63 to
346 0.21, $p=0.174$) BP following nitrate supplementation. There was a moderate, significant
347 negative correlation between the placebo-adjusted plasma nitrite concentrations and the
348 change in both systolic ($r=-0.76$, 90%CI: -0.90 to -0.47, $p<0.001$) and diastolic ($r=-0.51$,
349 90%CI: -0.77 to -0.10, $p=0.03$) BP following nitrate supplementation. The slope of the
350 regression line between the placebo-adjusted plasma nitrite concentration and the change in
351 systolic ($y=-0.016+1.791$) and diastolic ($y=-0.007+3.319$) BP was -0.016 (95%CI: -0.022 to -
352 0.010) and -0.007 (95%CI: -0.016 to 0.001), respectively. Supplementary Table 1 illustrates
353 the expected BP changes for a given plasma nitrite concentration.

354

355 **DISCUSSION**

356 This is the first study on the topic of dietary nitrate supplementation to follow a replicate
357 crossover design and associated expert guidance for data analysis (22, 25, 34). We detected
358 inter-individual differences in the effects of dietary nitrate supplementation on plasma nitrate
359 and nitrite concentrations and systolic BP that were distinguishable from random within-
360 subject variability. In addition, our data suggest that the effects of nitrate supplementation on
361 plasma nitrate and nitrite concentrations, and systolic BP are consistent within individuals
362 when measured on at least two occasions.

363 We observed a mean reduction in systolic BP following dietary nitrate
364 supplementation of 7 mmHg. A novel finding of our study is that the degree of systolic BP

365 reduction following nitrate supplementation, i.e., the treatment response was highly variable
366 between individuals, and greater than the within-participant trial-to-trial random variation.
367 Our study, therefore, supports the notion that there may be genuine ‘*responders*’ and ‘*non-*
368 *reponders*’(or, more accurately, higher and lower responders) to dietary nitrate
369 supplementation [17–20]. Application of a recently described meta-analytic approach for
370 replicate crossover trial examination revealed that the upper confidence interval for the
371 control-adjusted BP reduction following nitrate supplementation exceeded the MCID of 2
372 mmHg for approximately half (8/15) of our participants. This suggests that these individuals
373 are likely to experience BP reductions with nitrate supplementation of a magnitude which
374 could potentially contribute to mitigating CVD incidence and mortality [38, 53].

375 Nitrate supplementation also significantly reduced diastolic BP, with a mean
376 reduction of 6 mmHg. However, the between-replicate correlation for diastolic BP was low.
377 This suggests that the effects of nitrate on diastolic BP are not as clear (relative to the random
378 within-subjects variability) compared with systolic BP. This may help explain why reductions
379 in diastolic BP are less frequently observed in the extant literature [7]. The participant-by-
380 condition interaction was also small, suggesting inconsistent inter-individual variability in the
381 effects of nitrate supplementation on diastolic BP. It is currently unclear why there appears
382 to be repeatable interindividual differences in the effects of nitrate supplementation on
383 systolic, but not diastolic, BP. It is possible that there are measurement or experimental
384 issues that could obscure true inter-individual differences in diastolic BP responses, but more
385 research is needed to explicate this phenomenon.

386 The potential for evidence-based personalised recommendations around dietary nitrate
387 intake rests on formal identification of individual participants who will benefit most from
388 consumption of this compound [54]. This could be achieved by identifying participant
389 characteristics that are associated with the level of BP response to dietary nitrate. At the

390 group level, previous data suggests that nitrate supplementation may be more effective at
391 lowering BP in males versus females (although more studies in females are needed to confirm
392 this hypothesis) [15, 55] and in younger versus older adults [56, 57]. All participants in our
393 study were healthy young males which emphasises the importances of factors other than age,
394 sex and health in determining inter-individual responses to nitrate supplementation.
395 Following consumption, dietary nitrate is absorbed in the upper gastrointestinal tract,
396 increasing plasma nitrate concentrations [10]. Whilst most of the ingested nitrate is excreted
397 in urine, approximately 25% is returned to the oral cavity via the salivary glands [58] where it
398 is reduced to nitrite by oral bacteria [59]. This nitrite is swallowed and partly converted to
399 NO and other nitrogen oxides in the stomach. Some nitrite also reaches systemic circulation,
400 where it can be reduced to NO in various tissue [10]. Investigation of factors that may explain
401 inter-individual variations in response to nitrate supplementation could focus on key steps
402 within the gastrointestinal tract (including actions of oral bacteria involved in the regulation
403 of NO bioavailability [21, 60, 61] and stomach pH which influences non-enzymatic
404 conversation of nitrate to NO and other reactive nitrogen oxides [62]). Interestingly, recent
405 data from Willmott et al. [63] suggests that individuals with a greater oral nitrate reducing
406 capacity achieve a larger reduction in diastolic BP after nitrate supplementation. In addition,
407 research should further explore the impact of genetic variants (or other factors) that alter the
408 biological activity of the proteins e.g., nitric oxide synthases (NOS) involved in production of
409 NO from both nitrate and other dietary sources (e.g., L-arginine/L-citrulline). Hobbs et al.
410 [17] found that nitrate was more effective at lowering diastolic BP in T carriers (compared
411 with GG carriers) of the Glu298Asp polymorphism in the gene (*NOS3*) encoding eNOS [17].
412 To date, there has been no systematic investigation of these and other factors that may be
413 causally responsible for inter-individual differences in the response to nitrate supplementation

414 using appropriate designs such as replicate crossover studies. This is a priority for future
415 research with potential to be an important exemplar for precision nutrition.

416 Strengths of this study include the adoption of a replicate crossover study design and
417 the use of appropriate statistical approaches for quantifying between-participant outcome
418 response variability. This extends previous studies that have explored the impact of nitrate on
419 biological markers and/or BP in traditional crossover or parallel group designs [7] or with
420 repeat administration of nitrate *but not* control/placebo arms [21], such that the participant-
421 by-condition interaction could not be estimated. Undeniably, the repeated administration of
422 treatment and placebo for derivation of the person by treatment interaction complicates the
423 statistical analysis, but this is a necessary complication for appropriate study of this topic.
424 Unfortunately, previous researchers have arrived at erroneous claims about treatment
425 response heterogeneity on the basis of simple, but compromised, responder counting and
426 simply observing individual changes solely from the treatment group in a trial [23]. Potential
427 limitations include only recruiting healthy young males as participants. While this may
428 represent a limitation in generalisation of our findings to the general population, this design
429 feature was a distinct advantage in revealing evidence of true inter-individual variations in
430 physiological response to nitrate supplementation that cannot be explained by sex or age
431 differences alone. Whilst lowering BP in this group may be less of a public health priority
432 than individuals with hypertension, lowering BP in individuals who are not hypertensive
433 down to a least ~115/75 mmHg could reduce risk of vascular death [53]. A further limitation
434 is the relatively low sample size (n=15), although both the crossover (within-subjects) and
435 replicate aspects of our design increased statistical power (relative to a parallel arm study) for
436 detection of mean treatment effects. Our design and sample size also enabled the detection of
437 statistically significant individual differences in responses for all outcome variables apart
438 from diastolic BP. We cannot rule out the possibility that response heterogeneity in diastolic

439 BP would be detected with a larger sample size, more reliable measurements and/or a greater
440 number of replicates in the design. Repeated administration of treatments is the key aspect for
441 detecting, confidently, treatment response heterogeneity but laboratory-based and somewhat
442 invasive replicate crossover studies like ours are difficult to recruit for. Additionally, we
443 studied acute responses so it remains to be established whether there are similar inter-
444 individual differences in response to nitrate supplementation over longer intervention periods.
445 Longer-term interventions might also clarify whether the benefits of nitrate consumption on
446 CVD risk proposed in observational studies [64] occurs with prolonged dietary nitrate
447 supplementation, and whether benefits are restricted to certain population sub-
448 groups/individuals.

449 This study revealed evidence of substantial inter-individual differences in the
450 physiological responses (NO biomarkers and systolic BP) to dietary nitrate supplementation
451 in healthy young males. This provides proof-of-concept as a basis for further investigations of
452 the magnitude, durability and pervasiveness of these inter-individual responses across diverse
453 populations and of the (biological) factors responsible for the observed intra-individual
454 variation. These findings open up the exciting possibility of personalised recommendations
455 for dietary nitrate intake for optimal management of BP and related health outcomes.

456 **ACKNOWLEDGEMENTS**

457 We would like to thank our participants for giving up their time to take part in this study. In
458 addition, we would like to thank Mr Jack Williams for assisting with the plasma nitrate and
459 nitrite analyses.

460

461 **AUTHOR CONTRIBUTIONS**

462 OMS, EH, JCM, MS, RK, LL, GA, EW, JM and AG designed the research. EW generated
463 the random allocation sequence and ensured researchers involved in participant enrolment
464 and data collection (OMS, EH and SA) were blinded to the experimental conditions. EH, SA,
465 and OMS collected the data and MB and CE conducted the plasma nitrate/nitrite analyses.
466 GA, LL and OMS conducted the statistical analysis. OMS, EH, SA, MS, EW, RK, JM, AG,
467 MS, MB, CE, LL, GA and JCM critically interpreted the data. OMS, EH, SA, MS, EW, RK,
468 JM, AG, MS, MB, CE, LL, GA and JCM wrote the paper. OMS had primary responsibility
469 for the final content. All authors have read and approved the final manuscript.

470

471 **DECLARATIONS**

472 **Funding:** This study was funded by a grant from the Wellcome Trust Translational
473 Partnership. The salary of MS is supported by a Royal Perth Hospital Career Advancement
474 Fellowship and an Emerging Leader Fellowship from the Future Health Research and
475 Innovation Fund, Department of Health (Western Australia).

476

477 **Competing interests:** The authors have no relevant financial or non-financial interests to
478 disclose.

479

480

481 **DATA SHARING**

482 Data described in the manuscript, code book, and analytic code will be made available upon

483 request pending author approval.

484

485

REFERENCES

1. Zhou B, Perel P, Mensah GA, Ezzati M (2021) Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. *Nat Rev Cardiol* 18:785–802. <https://doi.org/10.1038/s41569-021-00559-8>
2. Olsen MH, Angell SY, Asma S, et al (2016) A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. *The Lancet* 388:2665–2712. [https://doi.org/10.1016/S0140-6736\(16\)31134-5](https://doi.org/10.1016/S0140-6736(16)31134-5)
3. Bundy JD, Li C, Stuchlik P, et al (2017) Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis. *JAMA Cardiol* 2:775–781. <https://doi.org/10.1001/jamacardio.2017.1421>
4. Williams B, Mancia G, Spiering W, et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens* 36:1953. <https://doi.org/10.1097/HJH.0000000000001940>
5. Larsen FJ, Ekblom B, Sahlin K, et al (2006) Effects of Dietary Nitrate on Blood Pressure in Healthy Volunteers. *N Engl J Med* 355:2792–2793. <https://doi.org/10.1056/NEJMc062800>
6. Webb AJ, Patel N, Loukogeorgakis S, et al (2008) Acute blood pressure lowering, vasoprotective and anti-platelet properties of dietary nitrate via bioconversion to nitrite. *Hypertension* 51:784–790. <https://doi.org/10.1161/HYPERTENSIONAHA.107.103523>
7. Jackson JK, Patterson AJ, MacDonald-Wicks LK, et al (2018) The role of inorganic nitrate and nitrite in cardiovascular disease risk factors: a systematic review and meta-analysis of human evidence. *Nutr Rev* 76:348–371. <https://doi.org/10.1093/nutrit/nuy005>
8. Hord NG, Tang Y, Bryan NS (2009) Food sources of nitrates and nitrites: the physiologic context for potential health benefits. *Am J Clin Nutr* 90:1–10. <https://doi.org/10.3945/ajcn.2008.27131>
9. Griffiths A, Alhulaefi S, Hayes EJ, et al (2023) Exploring the Advantages and Disadvantages of a Whole Foods Approach for Elevating Dietary Nitrate Intake: Have Researchers Concentrated Too Much on Beetroot Juice? *Appl Sci* 13:7319. <https://doi.org/10.3390/app13127319>
10. Lundberg JO, Weitzberg E, Gladwin MT (2008) The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. *Nat Rev Drug Discov* 7:156–167. <https://doi.org/10.1038/nrd2466>
11. Siervo M, Scialò F, Shannon OM, et al (2018) Does dietary nitrate say NO to cardiovascular ageing? Current evidence and implications for research. *Proc Nutr Soc* 77:112–123. <https://doi.org/10.1017/S0029665118000058>
12. Vanhatalo A, Bailey SJ, Blackwell JR, et al (2010) Acute and chronic effects of dietary nitrate supplementation on blood pressure and the physiological responses to moderate-

- intensity and incremental exercise. *AJP Regul Integr Comp Physiol* 299:R1121–R1131.
<https://doi.org/10.1152/ajpregu.00206.2010>
13. Jonvik KL, Nyakayiru J, Pinckaers PJ, et al (2016) Nitrate-Rich Vegetables Increase Plasma Nitrate and Nitrite Concentrations and Lower Blood Pressure in Healthy Adults. *J Nutr* jn229807. <https://doi.org/10.3945/jn.116.229807>
 14. Siervo M, Shannon O, Kandhari N, et al (2020) Nitrate-Rich Beetroot Juice Reduces Blood Pressure in Tanzanian Adults with Elevated Blood Pressure: A Double-Blind Randomized Controlled Feasibility Trial. *J Nutr* 150:2460–2468.
<https://doi.org/10.1093/jn/nxaa170>
 15. Kapil V, Milsom AB, Okorie M, et al (2010) Inorganic Nitrate Supplementation Lowers Blood Pressure in Humans: Role for Nitrite-Derived NO. *Hypertension* 56:274–281.
<https://doi.org/10.1161/HYPERTENSIONAHA.110.153536>
 16. Rammos C, Hendgen-Cotta UB, Sobierajski J, et al (2014) Dietary nitrate reverses vascular dysfunction in older adults with moderately increased cardiovascular risk. *J Am Coll Cardiol* 63:1584–1585. <https://doi.org/10.1016/j.jacc.2013.08.691>
 17. Hobbs DA, George TW, Lovegrove JA (2014) Differential effect of beetroot bread on postprandial DBP according to Glu298Asp polymorphism in the eNOS gene: a pilot study. *J Hum Hypertens* 28:726–730. <https://doi.org/10.1038/jhh.2014.16>
 18. Coggan AR, Broadstreet SR, Mikhalkova D, et al (2018) Dietary nitrate-induced increases in human muscle power: high versus low responders. *Physiol Rep* 6:e13575.
<https://doi.org/10.14814/phy2.13575>
 19. Wylie LJ, Kelly J, Bailey SJ, et al (2013) Beetroot juice and exercise: pharmacodynamic and dose-response relationships. *J Appl Physiol* 115:325–336.
<https://doi.org/10.1152/jappphysiol.00372.2013>
 20. James PE, Willis GR, Allen JD, et al (2015) Nitrate pharmacokinetics: Taking note of the difference. *Nitric Oxide*. <https://doi.org/10.1016/j.niox.2015.04.006>
 21. Liddle L, Burleigh MC, Monaghan C, et al (2019) Variability in nitrate-reducing oral bacteria and nitric oxide metabolites in biological fluids following dietary nitrate administration: An assessment of the critical difference. *Nitric Oxide* 83:1–10.
<https://doi.org/10.1016/j.niox.2018.12.003>
 22. Senn S (2016) Mastering variation: variance components and personalised medicine. *Stat Med* 35:966–977. <https://doi.org/10.1002/sim.6739>
 23. Atkinson G, Batterham AM (2015) True and false interindividual differences in the physiological response to an intervention. *Exp Physiol* 100:577–588.
<https://doi.org/10.1113/EP085070>
 24. Senn S (2019) Sample size considerations for n-of-1 trials. *Stat Methods Med Res* 28:372–383. <https://doi.org/10.1177/0962280217726801>

25. Senn S, Rolfe K, Julious SA (2011) Investigating variability in patient response to treatment – a case study from a replicate cross-over study. *Stat Methods Med Res* 20:657–666. <https://doi.org/10.1177/0962280210379174>
26. Muntner P, Shimbo D, Carey RM, et al (2019) Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. *Hypertension* 73:e35–e66. <https://doi.org/10.1161/HYP.0000000000000087>
27. Rogers SC, Khalatbari A, Gapper PW, et al (2005) Detection of human red blood cell-bound nitric oxide. *J Biol Chem* 280:26720–26728. <https://doi.org/10.1074/jbc.M501179200>
28. Bacchetti P (2010) Current sample size conventions: Flaws, harms, and alternatives. *BMC Med* 8:17. <https://doi.org/10.1186/1741-7015-8-17>
29. Lakens D (2022) Sample size justification. *Collabra Psychol* 33267
30. Goltz FR, Thackray AE, Atkinson G, et al (2019) True Interindividual Variability Exists in Postprandial Appetite Responses in Healthy Men But Is Not Moderated by the FTO Genotype. *J Nutr* 149:1159–1169. <https://doi.org/10.1093/jn/nxz062>
31. Goltz FR, Thackray AE, King JA, et al (2018) Interindividual Responses of Appetite to Acute Exercise: A Replicated Crossover Study. *Med Sci Sports Exerc* 50:758–768. <https://doi.org/10.1249/MSS.0000000000001504>
32. Atkinson G, Nevill AM (2001) Selected issues in the design and analysis of sport performance research. *J Sports Sci* 19:811–827. <https://doi.org/10.1080/026404101317015447>
33. Shen T, Thackray AE, King JA, et al (2024) Are There Interindividual Responses of Cardiovascular Disease Risk Markers to Acute Exercise? A Replicate Crossover Trial. *Med Sci Sports Exerc* 56:63–72. <https://doi.org/10.1249/MSS.0000000000003283>
34. Senn S (2024) The analysis of continuous data from n-of-1 trials using paired cycles: a simple tutorial. *Trials* 25:128. <https://doi.org/10.1186/s13063-024-07964-7>
35. Araujo A, Julious S, Senn S (2016) Understanding Variation in Sets of N-of-1 Trials. *PLOS ONE* 11:e0167167. <https://doi.org/10.1371/journal.pone.0167167>
36. Schabenberger O (2004) Mixed model influence diagnostics. In: *Proceedings of the twenty-ninth annual SAS Users Group International Conference; 2004 May 9-12: Cary (The United States): SAS Institute.* pp 189–29
37. West BT, Galecki AT (2012) An Overview of Current Software Procedures for Fitting Linear Mixed Models. *Am Stat* 65:274–282. <https://doi.org/10.1198/tas.2011.11077>
38. Stamler J, Rose G, Stamler R, et al (1989) INTERSALT study findings. Public health and medical care implications. *Hypertens Dallas Tex* 1979 14:570–577. <https://doi.org/10.1161/01.hyp.14.5.570>
39. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of

- prospectively-designed overviews of randomised trials. *Lancet Lond Engl* 362:1527–1535. [https://doi.org/10.1016/s0140-6736\(03\)14739-3](https://doi.org/10.1016/s0140-6736(03)14739-3)
40. Schwarzer G (2007) meta: An R package for meta-analysis. *R News* 40–45
 41. IntHout J, Ioannidis JP, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. *BMC Med Res Methodol* 14:25. <https://doi.org/10.1186/1471-2288-14-25>
 42. Langan D, Higgins JPT, Jackson D, et al (2019) A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. *Res Synth Methods* 10:83–98. <https://doi.org/10.1002/jrsm.1316>
 43. Veroniki AA, Jackson D, Viechtbauer W, et al (2016) Methods to estimate the between-study variance and its uncertainty in meta-analysis. *Res Synth Methods* 7:55–79. <https://doi.org/10.1002/jrsm.1164>
 44. Viechtbauer W (2007) Confidence intervals for the amount of heterogeneity in meta-analysis. *Stat Med* 26:37–52. <https://doi.org/10.1002/sim.2514>
 45. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods* 1:97–111. <https://doi.org/10.1002/jrsm.12>
 46. Borenstein M (2024) Avoiding common mistakes in meta-analysis: Understanding the distinct roles of Q, I-squared, tau-squared, and the prediction interval in reporting heterogeneity. *Res Synth Methods* 15:354–368. <https://doi.org/10.1002/jrsm.1678>
 47. Williams R (2012) Using the Margins Command to Estimate and Interpret Adjusted Predictions and Marginal Effects. *Stata J* 12:308–331. <https://doi.org/10.1177/1536867X1201200209>
 48. IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ (2016) Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open* 6:e010247. <https://doi.org/10.1136/bmjopen-2015-010247>
 49. Riley RD, Higgins JPT, Deeks JJ (2011) Interpretation of random effects meta-analyses. *BMJ* 342:d549. <https://doi.org/10.1136/bmj.d549>
 50. Velmurugan S, Gan JM, Rathod KS, et al (2016) Dietary nitrate improves vascular function in patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled study. *Am J Clin Nutr* 103:25–38. <https://doi.org/10.3945/ajcn.115.116244>
 51. Kapil V, Khambata RS, Robertson A, et al (2015) Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. *Hypertens Dallas Tex* 1979 65:320–327. <https://doi.org/10.1161/HYPERTENSIONAHA.114.04675>
 52. Babateen AM, Shannon OM, O’Brien GM, et al (2023) Moderate doses of dietary nitrate elicit greater effects on blood pressure and endothelial function than a high dose:

- A 13-week pilot study. *Nutr Metab Cardiovasc Dis NMCD* S0939-4753(23)00084-4.
<https://doi.org/10.1016/j.numecd.2023.02.024>
53. Lewington S, Clarke R, Qizilbash N, et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet Lond Engl* 360:1903–1913.
[https://doi.org/10.1016/s0140-6736\(02\)11911-8](https://doi.org/10.1016/s0140-6736(02)11911-8)
 54. Shannon OM, Easton C, Shepherd AI, et al (2021) Dietary nitrate and population health: a narrative review of the translational potential of existing laboratory studies. *BMC Sports Sci Med Rehabil* 13:65. <https://doi.org/10.1186/s13102-021-00292-2>
 55. Wickham KA, Spriet LL (2019) No longer beeting around the bush: a review of potential sex differences with dietary nitrate supplementation 1. *Appl Physiol Nutr Metab Physiol Appl Nutr Metab* 44:915–924. <https://doi.org/10.1139/apnm-2019-0063>
 56. Capper T, Clifford T, Taylor G, et al (2022) Ageing modifies acute resting blood pressure responses to incremental consumption of dietary nitrate: a randomised, cross-over clinical trial. *Br J Nutr* 1–12. <https://doi.org/10.1017/S0007114522001337>
 57. Shannon OM, Clifford T, Seals DR, et al (2022) Nitric oxide, aging and aerobic exercise: Sedentary individuals to Master’s athletes. *Nitric Oxide* 125–126:31–39.
<https://doi.org/10.1016/j.niox.2022.06.002>
 58. Qin L, Liu X, Sun Q, et al (2012) Sialin (SLC17A5) functions as a nitrate transporter in the plasma membrane. *Proc Natl Acad Sci U S A* 109:13434–13439.
<https://doi.org/10.1073/pnas.1116633109>
 59. Duncan C, Dougall H, Johnston P, et al (1995) Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate. *Nat Med* 1:546–551
 60. Burleigh MC, Liddle L, Monaghan C, et al (2018) Salivary nitrite production is elevated in individuals with a higher abundance of oral nitrate-reducing bacteria. *Free Radic Biol Med* 120:80–88. <https://doi.org/10.1016/j.freeradbiomed.2018.03.023>
 61. Burleigh M, Liddle L, Muggeridge DJ, et al (2019) Dietary nitrate supplementation alters the oral microbiome but does not improve the vascular responses to an acute nitrate dose. *Nitric Oxide Biol Chem* 89:54–63.
<https://doi.org/10.1016/j.niox.2019.04.010>
 62. Sanches-Lopes JM, Ferreira GC, Pinheiro LC, et al (2020) Consistent gastric pH-dependent effects of suppressors of gastric acid secretion on the antihypertensive responses to oral nitrite. *Biochem Pharmacol* 177:113940.
<https://doi.org/10.1016/j.bcp.2020.113940>
 63. Willmott T, Ormesher L, McBain AJ, et al (2023) Altered Oral Nitrate Reduction and Bacterial Profiles in Hypertensive Women Predict Blood Pressure Lowering Following Acute Dietary Nitrate Supplementation. *Hypertension* 80:2397–2406.
<https://doi.org/10.1161/HYPERTENSIONAHA.123.21263>

64. Tan L, Stagg L, Hanlon E, et al (2024) Associations between Vegetable Nitrate Intake and Cardiovascular Disease Risk and Mortality: A Systematic Review. *Nutrients* 16:1511. <https://doi.org/10.3390/nu16101511>